Key factors
sym | FLGT |
exch | US |
MCap | 601.30M |
Beta | 1.418 |
EPS | -5.63 |
Div date | 0000-00-00 |
Yesterday
sym | FLGT |
exch | US |
close | 20.03 |
50 Day MA | 22.82 |
200 Day MA | 28.04 |
52 Week High | 44.09 |
52 Week Low | 19.88 |
Target Price | 26.67 |
Market Cap Mln | 601.30 |
Share statistics
Shares Outstanding | 29.90M |
Shares Float | 19.88M |
Percent Institutions | 49.11 |
PercentInsiders | 32.58 |
SharesShort | 603.97K |
Short Ratio | 2.23 |
Shares Short Prior Month | 611.22K |
Short Percent | 3.669 |
Income
Revenue TTM | 289.21M |
Revenue Per Share TTM | 9.71 |
Quarterly Revenue Growth YOY | 4.100 |
Gross Profit TTM | 366.90M |
EBITDA | -46.5M |
Diluted Eps TTM | -5.63 |
Quarterly Earnings Growth YOY | -98.6 |
earning
Operating Margin TTM | -0.47 |
PEGRatio | 1.32 |
EPS Estimate Current Quarter | -0.29 |
EPS Estimate Current Year | -1.06 |
EPS Estimate Next Quarter | -0.23 |
EPS Estimate Next Year | -0.76 |
Earnings Share | -5.63 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Ebitda | -4.34 |
Enterprise Value Revenue | 0.737 |
Book Value /share | 38.31 |
Price Book MRQ | 0.547 |
Price Sales TTM | 2.148 |
ProfitMargin | -0.58 |
ReturnOnAssetsTTM | -0.03 |
ReturnOnEquityTTM | -0.14 |
Sector
Gic Group | Health Care Equipment & Services |
Gic Industry | Health Care Providers & Services |
Gic Sector | Health Care |
Gic Sub Industry | Health Care Services |
Industry | Diagnostics & Research |
Sector | Healthcare |
Codes
ISIN | US3596641098 |
CIK | 1674930 |
Code | FLGT |
CUSIP | 359664109 |
Employer Id Number | 81-2621304 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic |
info
Fiscal Year End | December |
ForwardPE | 7.936 |
Full Time Employees | 1184.0 |
IPODate | 2016-09-29 |
International Domestic | Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Fulgent Genetics Inc |
Address | 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 |
Country Name | USA |
Phone | 626-350-0537 |
Web URL | https://www.fulgentgenetics.com |
Logo URL | /img/logos/US/FLGT.png |
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.